9.27
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AVXL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$9.52
Offen:
$9.44
24-Stunden-Volumen:
3.56M
Relative Volume:
3.16
Marktkapitalisierung:
$796.24M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-48.17M
KGV:
-16.26
EPS:
-0.57
Netto-Cashflow:
$-37.10M
1W Leistung:
-6.93%
1M Leistung:
+4.45%
6M Leistung:
+8.55%
1J Leistung:
+81.41%
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
Firmenname
Anavex Life Sciences Corporation
Sektor
Branche
Telefon
844-689-3939
Adresse
630 5TH AVENUE, NEW YORK
Vergleichen Sie AVXL mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
AVXL
Anavex Life Sciences Corporation
|
9.27 | 817.71M | 0 | -48.17M | -37.10M | -0.57 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2022-12-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
2022-06-23 | Eingeleitet | Berenberg | Buy |
2021-09-23 | Eingeleitet | BTIG Research | Buy |
2020-12-16 | Bestätigt | H.C. Wainwright | Buy |
2020-09-28 | Eingeleitet | Ladenburg Thalmann | Buy |
2020-02-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
2019-06-18 | Eingeleitet | Janney | Buy |
2018-05-16 | Fortgesetzt | Maxim Group | Buy |
2018-03-08 | Eingeleitet | ROTH Capital | Buy |
2018-02-13 | Bestätigt | Maxim Group | Buy |
2017-09-29 | Fortgesetzt | Noble Financial | Buy |
2017-02-07 | Eingeleitet | Noble Financial | Buy |
2016-03-29 | Eingeleitet | FBR Capital | Outperform |
Alle ansehen
Anavex Life Sciences Corporation Aktie (AVXL) Neueste Nachrichten
Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’ - The Manila Times
Anavex Life Sciences Corp. Announces Oral Presentation on Alzheimer's Disease Care at Alzheimer Europe Conference - Quiver Quantitative
Oral Blarcamesine Presented at 35th Alzheimer Europe — Anavex Highlights ANAVEX®2-73-AD-004 IIb/III - Stock Titan
Will Anavex Life Sciences Corp. (12X1) stock keep high P E multiplesJuly 2025 Analyst Calls & Growth Focused Investment Plans - newser.com
Is Anavex Life Sciences Corp. (12X1) stock testing key supportWeekly Trade Report & Community Verified Trade Alerts - newser.com
Anavex Life Sciences (NASDAQ:AVXL) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Anavex Life Sciences (NASDAQ:AVXL) Receives Buy Rating from HC Wainwright - MarketBeat
HC Wainwright & Co. Reiterates Anavex Life Sciences (AVXL) Buy Recommendation - Nasdaq
Anavex Life Sciences stock rating reiterated at Buy by H.C. Wainwright - Investing.com
How Anavex Life Sciences Corp. stock reacts to global recession fearsBreakout Watch & Low Drawdown Momentum Ideas - newser.com
Long term hold vs stop loss in Anavex Life Sciences Corp.Analyst Downgrade & Community Consensus Stock Picks - newser.com
Tools to monitor Anavex Life Sciences Corp. recovery probabilityEarnings Risk Report & Advanced Technical Signal Analysis - newser.com
Anavex Life Sciences (NASDAQ:AVXL) Trading Up 8.7%Should You Buy? - MarketBeat
Anavex Life Sciences (Nasdaq:AVXL) Reports Positive Phase 2 Results for ANAVEX®3-71 in Schizophrenia - Kalkine Media
D. Boral Capital Maintains Anavex Life Sciences (AVXL) Buy Recommendation - Nasdaq
Is Anavex Life Sciences Corp a good long term investmentBollinger Bands Signals & Free Phenomenal Capital Appreciation - earlytimes.in
Anavex: ANAVEX 3-71 Could Potentially Offer Disease-Modifying Effects For Schizophrenia - Seeking Alpha
Anavex Life Sciences (NASDAQ:AVXL) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Anavex Life Sciences (AVXL): Analyst Reaffirms "Buy" Rating | AV - GuruFocus
Anavex Life Sciences Stock Just Shot Up 7% Today – Here’s An Important Update - Stocktwits
Anavex Life Sciences (AVXL) Shares Rise on Positive Trial Result - GuruFocus
Anavex Life Sciences Reports Positive Phase 2 Results for ANAVEX®3-71 in Schizophrenia Clinical Study Achieving Safety and Tolerability Endpoints - Quiver Quantitative
Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program - The Manila Times
Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia - The Manila Times
Anavex Life Sciences stock rises after positive schizophrenia drug trial - Investing.com
Anavex Develops Once-Daily Tablet for ANAVEX3-71 in Phase 1b Trial | AVXL Stock News - Stock Titan
Novel Schizophrenia Drug ANAVEX3-71 Shows Promise: Safe Profile and Reduced Brain Inflammation Markers - Stock Titan
Anavex Life Sciences (NASDAQ:AVXL) Receives “Buy” Rating from D. Boral Capital - Defense World
Alzheimer’s Disease Market: Epidemiology, Therapies, and Key Players | Anavex Life Sciences Corp., TauRx Therapeutics Ltd, BioVie Inc., AriBio Co., Ltd., Novo Nordisk A/S, AgeneBio, Neurim Pharmaceuti - Barchart.com
Anavex Life Sciences (NASDAQ:AVXL) Earns "Buy" Rating from D. Boral Capital - MarketBeat
Alzheimer's Disease Market: Epidemiology, Therapies, And Key Players Anavex Life Sciences Corp., Taurx Therapeutics Ltd, Biovie Inc., Aribio Co., Ltd., Novo Nordisk A/S, Agenebio, Neurim Pharmaceuti - Menafn.com
Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial - markets.businessinsider.com
Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer's Disease Trial - Investing News Network
Anavex Life Sciences Announces Publication of Oral - GlobeNewswire
70% Success Rate: Anavex's Once-Daily Oral Alzheimer's Drug Shows Breakthrough Results in Late-Stage Trial - Stock Titan
Why millennials buy Anavex Life Sciences Corp. (12X1) stockJuly 2025 PostEarnings & Daily Price Action Insights - newser.com
How Anavex Life Sciences Corp. stock valuations compare to rivalsJuly 2025 Selloffs & Verified Momentum Stock Ideas - newser.com
How to recover losses in Anavex Life Sciences Corp. stockJuly 2025 Drop Watch & Safe Entry Point Identification - newser.com
Real time pattern detection on Anavex Life Sciences Corp. stockMarket Volume Summary & Target Return Focused Stock Picks - newser.com
What drives PRCT stock priceMarket Sentiment Shifts & These 3 Stocks Could Change Your Portfolio - earlytimes.in
What drives Anavex Life Sciences Corp stock priceOptions Trading Strategies & Minimal Capital Growth Plans - earlytimes.in
What analysts say about Anavex Life Sciences Corp stockEquity Performance Review & Stocks With 200% Upside Potential - Early Times
How Anavex Life Sciences Corp. (12X1) stock trades pre earningsJuly 2025 Gainers & Free Safe Entry Trade Signal Reports - newser.com
H.C. Wainwright Reiterates Its ‘Buy’ Rating on Anavex Life Sciences Corp. (AVXL) with a $42 Price Target - Insider Monkey
Anavex Life Sciences Corp. $AVXL Shares Sold by Goldman Sachs Group Inc. - MarketBeat
Published on: 2025-09-22 05:58:42 - newser.com
Aug Drivers: Can Anavex Life Sciences Corp weather a recessionSwing Trade & Low Risk Entry Point Guides - خودرو بانک
Aug Technicals: What is the PEG ratio of Anavex Life Sciences CorpJuly 2025 Intraday Action & Accurate Entry and Exit Point Alerts - خودرو بانک
Should I hold or sell Anavex Life Sciences Corp now2025 EndofYear Setup & Accurate Intraday Trade Tips - خودرو بانک
What momentum shifts mean for Anavex Life Sciences Corp.Inflation Watch & Technical Pattern Alert System - newser.com
Short interest data insights for Anavex Life Sciences Corp.2025 Growth vs Value & Scalable Portfolio Growth Methods - newser.com
Finanzdaten der Anavex Life Sciences Corporation-Aktie (AVXL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Anavex Life Sciences Corporation-Aktie (AVXL) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Thomas Steffen | Director |
Jun 05 '25 |
Option Exercise |
1.76 |
50,000 |
88,000 |
55,000 |
MISSLING CHRISTOPHER U | President and CEO |
Mar 24 '25 |
Option Exercise |
0.92 |
500,000 |
460,000 |
1,750,210 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):